

January 16, 2026

The Manager- Listing

**BSE Limited**

Corporate Relationship Dept., 5<sup>th</sup> Floor, New Trading Ring  
Rotunda Building, P J Towers, Dalal Street, Fort,  
Mumbai – 400 001

The Manager- Listing

**National Stock Exchange of India Limited**

Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block  
Bandra – Kurla Complex, Bandra (E),  
Mumbai – 400 051

Dear Sir/Madam,

**Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that the Company has received a final assessment order from the assessment unit being passed under section 143(3) read with section 144C(13) and 144(B) of the Income Tax Act, 1961 for assessment year 2022-23 on January 16, 2026.

The captioned final assessment order is a subsequent development to the draft order received earlier, which was disclosed to the stock exchanges vide our letter dated March 19, 2025.

In this regard, please find the details as required under the SEBI Circular SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023 attached herewith as **Annexure – A**.

Kindly take the above information on record.

Thanking You

**For AstraZeneca Pharma India Limited**

Bhavana Agrawal

Chief Financial Officer and Director

### Annexure – A

Sl. No.	Particulars	Details
1.	Name of the opposing party	Assessment Unit, Income tax department
2.	Brief details of dispute/litigation	Company has received a final assessment order from the Assessment Unit being passed under section 143(3) read with section 144C(13) and 144(B) of the Income Tax Act, 1961 for assessment year 2022-23, wherein adjustment on the legacy transfer pricing and corporate tax issues have been proposed.
3.	Court/tribunal/agency where the litigation is filed	The matter will be challenged before the Income-tax Appellate Tribunal (ITAT) by filing an appeal.
4.	Expected financial implications, if any, due to compensation, penalty etc	Matter will be suitably challenged in due course. The expected overall financial implication cannot be determined at this stage.
5.	Quantum of claims, if any	Rs. 11.88 crores (approx.) excluding interest and penalty.